A5001308210- Ovarian cancer diagnosis and treatment
- Intraperitoneal and Appendiceal Malignancies
- Endometrial and Cervical Cancer Treatments
- Endometriosis Research and Treatment
- Appendicitis Diagnosis and Management
- Cervical Cancer and HPV Research
- Cancer survivorship and care
- Renal cell carcinoma treatment
- Childhood Cancer Survivors' Quality of Life
- Colorectal and Anal Carcinomas
- Immunotherapy and Immune Responses
- BRCA gene mutations in cancer
- Uterine Myomas and Treatments
- Neuroblastoma Research and Treatments
- Virus-based gene therapy research
- Pituitary Gland Disorders and Treatments
- Testicular diseases and treatments
- CRISPR and Genetic Engineering
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Surgical Treatments
- Sarcoma Diagnosis and Treatment
- Cancer Risks and Factors
- Hernia repair and management
- Neuroendocrine Tumor Research Advances
- Cancer Research and Treatments
The Netherlands Cancer Institute
2016-2025
Oncode Institute
2017-2025
Society of Surgical Oncology
2024
Ludwig-Maximilians-Universität München
2024
Centre Hospitalier de l’Université de Montréal
2024
Princess Margaret Cancer Centre
2024
Centre Hospitalier Universitaire de Liège
2024
Queen's University
2024
Centre hospitalier universitaire de Québec
2024
Institut Claudius Regaud
2024
Treatment of newly diagnosed advanced-stage ovarian cancer typically involves cytoreductive surgery and systemic chemotherapy. We conducted a trial to investigate whether the addition hyperthermic intraperitoneal chemotherapy (HIPEC) interval would improve outcomes among patients who were receiving neoadjuvant for stage III epithelial cancer.In multicenter, open-label, phase 3 trial, we randomly assigned 245 had at least stable disease after three cycles carboplatin (area under curve 5 6 mg...
BackgroundRetrospective data suggest that the incidence of parametrial infiltration is low in patients with early-stage low-risk cervical cancer, which raises questions regarding need for radical hysterectomy these patients. However, from large, randomized trials comparing outcomes and simple are lacking.MethodsWe conducted a multicenter, randomized, noninferiority trial including lymph-node assessment cancer (lesions ≤2 cm limited stromal invasion). The primary outcome was recurrence pelvic...
The European Society of Gynaecological Oncology, the for Medical Oncology (ESMO) and Pathology held a consensus conference (CC) on ovarian cancer 15-16 June 2022 in Valencia, Spain. CC panel included 44 experts management pathology, an ESMO scientific advisor methodologist. aim was to discuss new or contentious topics develop recommendations improve harmonise patients with cancer. Eighteen questions were identified discussion under four main topics: (i) pathology molecular biology, (ii)...
The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to lymphadenectomy (IFL) vulvar patients with metastatic sentinel node (SN).GROINSS-V-II was prospective multicenter phase-II single-arm treatment trial, including early-stage (diameter < 4 cm) without signs of lymph involvement at imaging, who had primary surgical (local excision SN biopsy). Where the involved (metastasis any size), given...
The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery improves recurrence-free and overall survival in patients with FIGO stage III ovarian cancer who are ineligible for primary surgery. effect HIPEC remains undetermined candidates surgery.The objective is evaluate the on epithelial treated resulting no residual disease, or disease up 2.5 mm maximum dimension.We hypothesize that cancer.This international, randomized, open-label, phase trial will...
LBA5511 Background: In the last 2 decades, there has been a trend towards less radical surgery in patients with low-risk cervical cancer. Retrospective data suggested that may be safe and associated morbidity. The objective of this non-inferiority phase III prospective randomized trial was to compare RH SH women LRESCC. Methods: Women LRESCC defined as stage 1A2 or 1B1 lesion ≤ 2cm were after stratification by cooperative group, intended use sentinel node mapping, stage, histological type,...
Human papillomavirus type 16 (HPV16)-encoded E7 oncoprotein is constitutively expressed in cervical carcinoma cells and required for cellular transformation to be maintained. The protein, therefore, forms an attractive target T-cell–mediated immune intervention prevent or treat HPV16+ tumors. authors performed a peptide-based phase I/II vaccination trial induce anti-tumor responses patients with recurrent residual carcinoma. Fifteen HLA-A*0201+ received vaccinations synthetic peptides...
(Abstracted from N Engl J Med 2018;378:230–240) The majority of patients with ovarian cancer (OC) receive an initial diagnosis advanced disease that has spread the ovaries to peritoneal surface. most effective treatment for is cytoreductive surgery followed by systemic chemotherapy.
Nuclear extracts from adenovirus type 5 (Ad5) infected HeLa cells were used to study the template requirements for DNA replication in vitro. When Xba I digested Ad5 DNA, containing parental terminal protein (TP), was as a preferential synthesis of fragments observed. The newly synthesized covalently bound 82 kD preterminal (pTP).